Home Japan - www.pronexus.se
Search - www.pronexus.se
Home - www.pronexus.se

Highlights

August 26, 2015, Stockholm, Sweden

Pronexus is a partner in the EU-funded (H2020-PHC-2015) research project "Developing new therapies for Batten disease" (BATCure). The goal of the project is to advance the development of new therapeutic options for a group of rare diseases - neuronal ceroid lipofuscinoses (NCL) or Batten disease. The NCLs are devastating and debiliating genetic disorders that mainly affect children, who suffer progressive dementia and motor decline, visual failure and epilepsy, leading to a long period of complete dependence on care givers, and eventually a premature death. There are no curative treatments in the clinic for any type of NCL. The project combines the expertise of recognized European research teams, both basic scientists and clinicians, high-technology SMEs and micro-SMEs, and an NCL patients’ organisation. This multidisciplinary and cross-sectoral, scientific and medical interactive European group aims to develop innovative therapies for Batten disease. Pronexus part will include neurochemical monitoring of new treatments on mouse models of Batten disease.

 October 1, 2013, Stockholm, Sweden

Pronexus becomes a partner in the EU-funded research project (EU-FP7-Health) HUMAN (Health and the Understanding of Metabolism, Aging and Nutrition). The objective of the project is to study the function of genetic risk variants associated to metabolic diseases with the use of mouse models with humanised liver and pancreas.
The HUMAN consortium associates a core of outstanding basic research institutions to leading European biotech SMEs taking advantage of both academic and SME partners who have the ad hoc facilities. The main goal of HUMAN is to offer European research and industries exclusive tools to tackle the challenge of functional validation of metabolic disease-associated genetic variants by offering: i) innovative and robust humanised animal and cellular models; ii) a portfolio of new and validated therapeutic targets for better understanding of metabolic diseases and healthy aging. HUMAN will generate iPSCs biobanks and comprehensively manage all associated information, including clinical and metabolic profiles of the donors, the phenotypes of iPSCs and of the different humanised mice, using state of the art technologies (proteomics, metabolomics, epigenomics, transcriptomics, glycomics). In sum, the HUMAN consortium is uniquely situated to drive innovation towards a better knowledge of the genetic basis of major human metabolic diseases, thereby contributing to the understanding of healthier aging of Europeancitizens.

September 16-20, 2012, London, UK. Monitoring Molecules in Neuroscience: 14th International Conference

Jan Kehr presented a lecture entitled "Use of microdialysis in translationa research", with coauthors Takashi Yoshitake from Karolinska Institutet, Stockholm, and Bengt Dahlström and Folke Sjöberg from CTC Clinical Trial Consultants in Uppsala, Sweden. Microdialysis, voltammetric and biosensor techniques undoubtedly became the most widespread in vivo monitoring technologies in experimental neuropharmacology and neuroscience. However, the invasive character of these methods confines their clinical applicability mostly to neuromonitoring in intensive care, open and reconstructive surgery or to the use of microdialysis in organs such as skin or skeletal muscles. The purpose of the current effort is to use skin and/or muscle microdialysis, which are equally applicable both on healthy animals and humans, for monitoring effects of locally administered test compounds on the biomarker molecules, which might be associated with common PNS and CNS pathways. This makes it possible to use microdialysis as a truly translational technique for evaluation of drug effects from animal to human - for vascular microdosing and phase I trials. A complete abstract can be found on the conference website www.monitoringmolecules.org.

November 12-16, 2011, Washington, DC, USA. Society for Neuroscience

Pronexus Analytical presented a poster (KK13; 689.22) on Tuesday, November 15, Hall A-C, 1.00pm -3.00pm, entitled: “Designer drug mephedrone, compared to MDMA (ecstasy) and amphetamine, rapidly increases both dopamine and serotonin levels in nucleus accumbens of awake rats".

November 13-17, 2010, San Diego, CA, USA. Society for Neuroscience 40th Annual Meeting

Pronexus Analytical together with a client company Schwabe, Germany presented a poster (#162.6) on Sunday, Nov. 14, 9:00-10:00, entitled: “Effects of intraperitoneal administration of Silexan, an essential oil from flowers of Lavandula angustifolia on extracellular levels of noradrenaline, dopamine and serotonin in the prefrontal cortex of freely moving rats”. The microdialysis data support the clinically observed relaxing and anxiolytic actions of Silexan. During the last years, Pronexus scientists have carried-out several microdialysis and behavioral studies aiming to elucidate the mechanisms of action and the effects of herbal remedies, nutrients and thier active constituents on brain neurotransmission and metabolism.

September 12-16, 2010, Brussels, Belgium. Monitoring Molecules in Neuroscience. 13th International Conference on In Vivo Methods

Jan Kehr presented an opening Plenary Lecture entitled "Monitoring molecules in neuroscience: 50 years". The pdf version of this historical overview is available upon request. During the last 50 years, the development of techniques and methods for monitoring brain chemical signals, tissue metabolism and even targeted delivery and clearance of drugs and molecular labels have received considerable attention by scientific community, hospital care practitioners and manufacturers of medical devices. Current technologies for monitoring molecules or signals reflecting functional changes in brain chemistry include 1) minimally invasive techniques and 2) neuroimaging techniques. The techniques within the first group are widely used in experimental medicine and pharmacology, whereas neuroimaging techniques have been established predominantly in clinical neuroradiology. There is a great potential for further development and new applications of microdialysis and biosensor technologies as the key techniques in pharmacological neurochemistry in vivo and in studies on neurochemical basis of behavior. Further advancements in development of less invasive, more specific and sensitive devices and methods are warranted and expected to strengthen the use of in vivo monitoring techniques in functional pharmacology and enabling more efficient searching for novel biomarkers of CNS diseases.

当社は、2008年5月1日よりエイコム社と協同でマイクロダイアリシスの受託研究を始めました。エイコム社は、日本国内における皆様の窓口となり、受託研究は当社で行います。当社とエイコム社は、責任を持って皆様の要望にお答えしたいと考えております。